Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

NCT04582864 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

11

Enrollment

OTHER

Sponsor class

Stopped The sponsor is no longer supporting the drug

Conditions

Relapsed Acute Myeloid Leukemia

Interventions

DRUG: Flotetuzumab
PROCEDURE: Donor lymphocyte infusion

Sponsor

Washington University School of Medicine

Collaborators

[object Object]
[object Object]